Il seminario si svolgerà in lingua inglese.
ABSTRACT
Lipid nanoparticles have contributed significantly to a paradigm shift in drug delivery. In 1991, solid lipid nanoparticles (SLN) were introduced as a new, cutting-edge carrier system for drugs. These nanoscale (40 to 1000 nm) carriers are composed of biodegradable and biocompatible solid lipids, stabilized with aqueous emulsifiers. SLN can be made from pure lipids or a mixture of different lipids and emulsifiers, and are chosen based on the desired administration route to prevent particle clumping. In the early 2000s, a new generation of lipid nanoparticles, called nanostructured lipid carriers (NLC), were developed to address limitations of SLN, such as low drug loading and stability. NLC are made of a blend of solid and liquid lipids, resulting in a more flexible and smart matrix that allows for higher drug loading and stability. With excellent tolerability, low toxicity, stability, drug targeting capabilities, and affordability, lipid nanoparticles are a highly attractive option for improved drug delivery.
Our research focuses on developing nanosystems based on solid lipid matrix nanoparticles for drug administration through various routes, including dermal, transdermal, oral, and intravenous, with the goal of overcoming biological barriers and improving targeted drug delivery. Specifically, we are exploring innovative strategies such as peptide conjugates, inorganic (gold and iron) decoration, and biomimetic membranes to enhance the targeted delivery of repurposed drug and gene material to address several unmet medical needs.